P. Pisani, M. D. Renna, F. Conversano, E. Casciaro, D. Paola et al., Major osteoporotic fragility fractures: Risk factor updates and societal impact, World J Orthop, vol.7, issue.3, pp.171-81, 2016.
DOI : 10.5312/wjo.v7.i3.171

URL : https://doi.org/10.5312/wjo.v7.i3.171

E. I. Klaver, H. C. Van-loon, R. Stienstra, T. P. Links, J. C. Keers et al., Thyroid hormone status and health-related quality of life in the LifeLines Cohort Study, Thyroid, vol.23, issue.9, pp.1066-73, 2013.

U. E. Tröhler and T. Kocher, J R Soc Med, vol.107, issue.9, pp.376-383, 2014.

F. H. Doyle, Nonparathyroid Endocrine Bone Disease, Proc R Soc Med, vol.60, issue.11, pp.1131-1132, 1967.

Z. Yan, H. Huang, J. Li, and J. Wang, Relationship between subclinical thyroid dysfunction and the risk of fracture: a meta-analysis of prospective cohort studies, Osteoporos Int, vol.27, issue.1, pp.115-140, 2016.

T. Diamond, L. Nery, and I. Hales, A therapeutic dilemma: suppressive doses of thyroxine significantly reduce bone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinoma, J Clin Endocrinol Metab, vol.72, issue.6, pp.1184-1192, 1991.

M. K. Kim, K. J. Yun, M. H. Kim, D. J. Lim, H. S. Kwon et al., The effects of thyrotropin-suppressing therapy on bone metabolism in patients with welldifferentiated thyroid carcinoma, Bone, vol.71, pp.101-106, 2015.

B. Uzzan, J. Campos, M. Cucherat, P. Nony, J. P. Boissel et al., Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis, J Clin Endocrinol Metab, vol.81, issue.12, pp.4278-89, 1996.

A. Viniol, L. Hickstein, J. Walker, N. Donner-banzhoff, E. Baum et al., Influence of thyroid hormone therapy on the fracture rate-A claims data cohort study, Bone, vol.86, pp.86-90, 2016.

J. A. Franklyn, J. Betteridge, J. Daykin, R. Holder, G. D. Oates et al., Longterm thyroxine treatment and bone mineral density, Lancet, vol.340, issue.8810, pp.9-13, 1992.

P. Vestergaard, L. Rejnmark, and L. Mosekilde, Influence of hyper-and hypothyroidism, and the effects of treatment with antithyroid drugs and levothyroxine on fracture risk, Calcif Tissue Int, vol.77, issue.3, pp.139-183, 2005.

R. Schneider, M. Schneider, C. Reiners, and P. Schneider, Effects of levothyroxine on bone mineral density, muscle force, and bone turnover markers: a cohort study, J Clin Endocrinol Metab, vol.97, issue.11, pp.3926-3960, 2012.

L. Feng, S. C. Scherer, B. Y. Tan, G. Chan, N. P. Fong et al., Comorbid cognitive impairment and depression is a significant predictor of poor outcomes in hip fracture rehabilitation, Int Psychogeriatr, vol.22, issue.2, pp.246-53, 2010.

E. V. Grue, M. Kirkevold, P. Mowinchel, and A. H. Ranhoff, Sensory impairment in hipfracture patients 65 years or older and effects of hearing/vision interventions on fall frequency, J Multidiscip Healthc, 2008.

, Dose/kg of Levothyroxine treatment (ref: 0.5 ug/kg et +)

, Dose/day of Levothyroxine treatment (ref: 50 ug/day et +)

K. Antivitamine,

. Thiazide and . Treatment,

, Biphosphonate treatment (ref: no)

, High dose of steroids treatment

, Steroids treatment (ref: no)

, Diabetes

D. Vitamino and . Calcium-supplementation,

. Breastfeeding,

, HRT therapy

. Smoking,

, Psychotropic treatment (ref: one psychotropic treatment)

, OR : Odds Ratio; CI : Confidence Interval; HRT : hormone replacement therapy. * Stepwise variable selection with significance level for entry into the model at 0.2 and with significance level for staying in the model at 0.05 were used